Revolution Medicines

REDWOOD CITY, Calif. — September 14, 2026 Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA)...

REDWOOD CITY, Calif., Sept. 2, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a commercial-stage oncology company focused on RAS-driven cancers,...

Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...

REDWOOD CITY, Calif., August 26, 2026 Revolution Medicines, Inc. has received U.S. Food and Drug Administration (FDA) approval for...

San Carlos, Calif. & Redwood City, Calif., August 10, 2026 BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a...

Revolution Medicines, Redwood City, Calif., July 22, 2026 Revolution Medicines announced that the U.S. Food and Drug Administration (FDA)...

REDWOOD CITY, Calif., July 7, 2026 Revolution Medicines has announced a major regulatory milestone as the European Medicines Agency...

REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...

REDWOOD CITY, Calif., June 24, 2026 Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio...

REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...